Table 2

 Concentration of fluid phase complement activation products and complement activator molecules in synovial fluid and plasma of RA patients and plasma of healthy individuals

RA synovialfluidp Value†RA plasmap Value‡Control plasmap Value
Data are presented as mean (SD). Differences were analysed with one-way ANOVA, followed by Bonferroni’s multiple comparison test. Two-tailed significance levels are provided (p), which were considered significant at p<0.05. NS, not significant; *p<0.05; **p<0.01; ***p<0.001.
†Differences between RA synovial fluid and RA plasma. ‡Differences between RA plasma and control plasma. ¶Differences between RA synovial fluid and control plasma.
C4b/c (nmol/l)62.9 (67.4)*10.4 (6.7)NS5.8 (3.6)**
C3b/c (nmol/l)262.0 (232.6)**29.6 (8.2)NS16.3 (4.5)**
CRP (mg/l)18.0 (14.1)NS40.3 (29.2)***2.7 (2.6)NS
SAP (mg/l)13.8 (9.8)***91.6 (27.0)NS70.8 (16.5)***
IgM (g/l)0.3 (0.3)NS0.7 (0.5)NS0.8 (0.6)NS
IgG (g/l)5.1 (1.5)**9.7 (3.0)NS9.2 (2.3)**